In addition, as the core strategy of T2D management has been evolving from glycemic control to organ protection, the ocular therapeutic or adverse effects of novel antidiabetic drugs have been somewhat neglected.48 To our knowledge, this study is the first to report that SGLT2 inhibitors were associated with a decreased risk of DED compared with GLP-1 RAs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.